2013 Volume 66 Issue 10 Pages 709-712
Fifteen dogs with pituitary tumors were treated with a weekly schedule of hypofractionated three-dimensional conformal radiation therapy (3D-CRT). The median total dose was 48 Gy (range: 35-52 Gy), with a median irradiation dose/fraction of 7 Gy (5-8 Gy). The median follow-up time was 298 days. Twelve dogs were alive at the time of analysis. One dog died before completing the course of radiation therapy. Two died at 372 and 479 days after 3D-CRT. Although six of the 13 dogs with pituitary-dependent hyperadrenocorticism had improvement of clinical signs, none were able to stop receiving trilostane. Of the 13 dogs with neurologic signs, 10 had complete resolution and three had partial resolution. None of the dogs developed acute or late adverse effects due to 3D-CRT. Our preliminary results suggest that hypofractionated 3D-CRT was feasible in dogs with pituitary tumors.
